Sjögren syndrome is a chronic autoimmune disease in which your immune system attacks the glands that produce moisture, primarily your tear and salivary glands. This leads to persistent dry eyes and dry mouth, but the condition often extends well beyond dryness, causing fatigue, joint pain, and problems in organs throughout the body. It affects women roughly six times more often than men, with prevalence estimated at about 14 per 100,000 adults.
How the Immune System Causes Damage
In a healthy body, exocrine glands (the glands responsible for producing tears, saliva, and other secretions) function without interference. In Sjögren syndrome, immune cells, mainly a type of white blood cell called T lymphocytes, begin clustering around the ducts inside salivary glands and tear glands. Over time, these clusters grow and replace the tissue that normally produces moisture. In more severe cases, B cells and plasma cells join in, driving chronic inflammation that progressively destroys gland function.
This isn’t just a local problem. The immune system becomes broadly overactive, with abnormal signaling molecules ramping up B cell activity throughout the body. That widespread immune dysfunction explains why Sjögren syndrome can affect joints, nerves, lungs, and skin, not just the glands that make tears and saliva.
The Core Symptoms: Dryness, Fatigue, and Pain
The classic symptom triad is dryness (called “sicca”), fatigue, and pain. Dry eyes often feel like a foreign body sensation, with burning and increased light sensitivity. Dry mouth makes it hard to chew dry foods, swallow comfortably, or speak for extended periods. But dryness can also affect other mucous membranes, leading to chronic cough, heartburn, sore throat, and recurrent urinary tract infections. Between 61 and 68 percent of women with Sjögren syndrome report vaginal dryness causing pain during sex.
Fatigue in Sjögren syndrome is often severe and persistent, not the kind that improves with a good night’s sleep. Joint pain ranks among the most common complaints, affecting anywhere from 15 to 90 percent of patients depending on the study. It typically appears as intermittent, symmetrical swelling in multiple joints that doesn’t cause permanent joint destruction, distinguishing it from conditions like rheumatoid arthritis. Muscle pain is also common.
Neurological symptoms show up in 18 to 45 percent of cases, sometimes even before the diagnosis is made. Three-quarters of patients show some degree of cognitive impairment, and many develop depression or anxiety.
Not All Dryness Is Sjögren Syndrome
Dry eyes and dry mouth are extremely common, especially with aging, medications, and screen use. Only about 10 percent of people with clinically significant dry eye syndrome actually have Sjögren syndrome. At the same time, roughly 20 percent of people with confirmed Sjögren syndrome don’t have noticeable dryness at all. Their disease may first appear as joint pain, nerve problems, or swollen salivary glands. This mismatch means the condition is frequently missed or misdiagnosed in both directions.
How Sjögren Syndrome Is Diagnosed
Diagnosis relies on a combination of blood tests, eye tests, and sometimes a small tissue sample from the inner lip. The current classification system, developed jointly by the American College of Rheumatology and the European League Against Rheumatism in 2016, uses a weighted scoring system across five items. A total score of 4 or higher confirms the diagnosis in someone already showing suggestive symptoms.
The two highest-weighted items, each scoring 3 points, are a positive blood test for anti-SSA (Ro) antibodies and a lip biopsy showing clusters of at least 50 immune cells per section of salivary gland tissue. Either one alone nearly meets the diagnostic threshold. Three additional tests each contribute 1 point: an eye surface staining test that reveals damage from dryness, a Schirmer test measuring tear production (positive if the paper strip wets 5 millimeters or less in five minutes), and an unstimulated saliva flow rate below 0.1 milliliters per minute.
In practice, many patients are diagnosed through the antibody blood test combined with one or two of the simpler clinical tests, without needing a biopsy. But when blood tests are negative and suspicion remains high, the lip biopsy becomes essential.
Primary Versus Secondary Sjögren Syndrome
Sjögren syndrome is called “primary” when it occurs on its own and “secondary” when it develops alongside another autoimmune disease, most commonly lupus or rheumatoid arthritis. The symptoms overlap considerably, but primary Sjögren syndrome is more likely to involve systemic complications like lung or kidney involvement. Secondary Sjögren syndrome tends to be recognized later because its dryness symptoms are often attributed to the existing autoimmune condition.
Lymphoma and Other Serious Complications
The most serious long-term risk is non-Hodgkin lymphoma. People with Sjögren syndrome face an estimated 10 to 48 times the lymphoma risk of the general population, a higher increase than what’s seen in lupus or rheumatoid arthritis. This elevated risk stems from the chronic B cell overactivity that defines the disease. Not everyone develops lymphoma, but persistent swelling of the salivary glands, certain blood marker changes, and severe gland inflammation are warning signs that doctors monitor closely.
Lung involvement is another concern. Interstitial lung disease, where inflammation gradually scars lung tissue, carries an average survival time of about 9 years after diagnosis, though many cases remain mild. A four-fold increased risk of death over 10 years has been reported in patients who develop this complication.
Life Expectancy and Long-Term Outlook
For most people, Sjögren syndrome is a slow-progressing, chronic condition rather than a life-threatening one. The 10-year survival rate after diagnosis is above 90 percent. The 5-year survival rate sits at roughly 95 percent. Overall mortality is modestly higher than in the general population, with some studies finding about twice the expected death rate within 7 years of diagnosis, driven largely by the subset of patients who develop lymphoma or lung disease.
Quality of life is where the disease exacts its heaviest toll. The combination of constant dryness, fatigue, cognitive difficulties, and pain can significantly affect work, relationships, and daily functioning. Many patients describe the fatigue and brain fog as more disabling than the dryness itself. Treatment focuses on managing symptoms: artificial tears and saliva substitutes for dryness, medications that stimulate remaining gland function, and immune-suppressing drugs for patients with significant organ involvement. The goal is preserving gland function as long as possible while controlling inflammation that could damage other organs.